Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with Anti-HER2 therapy

Clinical Cancer Research

Volumn 21, Issue 17, 2015, Pages 3995-4003

  Giuliano, Mario ^a,b   Hu, Huizhong ^a   Wang, Yen Chao ^a   Fu, Xiaoyong ^a   Nardone, Agostina ^a   Herrera, Sabrina ^a   Mao, Sufeng ^a   Contreras, Alejandro ^a   Gutierrez, Carolina ^a   Wang, Tao ^a   Hilsenbeck, Susan G ^a   Angelis, Carmine D ^a   Wang, Nicholas J ^c   Heiser, Laura M ^c   Gray, Joe W ^c   Lopez Tarruella, Sara ^d   Pavlick, Anne C ^a   Trivedi, Meghana V ^a,e   Chamness, Gary C ^a   Chang, Jenny C ^f   Osborne, C Kent ^a   Rimawi, Mothaffar F ^a   Schiff, Rachel ^a   more..

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c Oregon Health and Science University Department of Biomedical Engineering   (United States)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e UNIVERSITY OF HOUSTON   (United States)

^f HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTINEOPLASTIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FULVESTRANT; GEFITINIB; LAPATINIB; PERTUZUMAB; PROGESTERONE RECEPTOR; PROTEIN BCL 2; TRASTUZUMAB; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BIOLOGICAL MARKER; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; BREAST TUMOR; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INHIBITION KINETICS; MCF 7 HER2 18 CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT; UACC812 CELL LINE; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; NEOADJUVANT THERAPY; TIME FACTOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOMARKERS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; MICE; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; PROTO-ONCOGENE PROTEINS C-BCL-2; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942859248     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2728     Document Type: Article

References (37)

1. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
3. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993; 11:1936-42.
4. Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog 2012;17:1-16.
5. Tortora G. Mechanisms of resistance to HER2 target therapy. J Natl Cancer Inst Monogr 2011;2011:95-8.
6. Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, et al. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers-role of estrogen receptor and HER2 reactivation. Breast Cancer Res 2011;13:R121.
7. Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 2007;99:694-705.
8. Rimawi MF, Wiechmann LS, Wang YC, Huang C, Migliaccio I, Wu MF, et al. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res 2011;17:1351-61.
9. Nahta R, O'Regan RM. Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. Breast Cancer Res Treat 2012; 135:39-48.
10. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25-32.
11. Baselga J, Bradbury I, Eidtmann H, DiCosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379:633-40.
12. Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, orbothinhuman epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 2012;30: 1989-95.
13. Holmes FA, Espina V, Liotta LA, Chang JC, Nagarwala YX, Danso M, et al. Correlation of clinical and molecular findings with pathologic response to preoperative lapatinib and trastuzumab, separately or in combination, prior to neoadjuvant chemotherapy for HER2 positive breast cancer. Cancer Res 2011;71(24, Supplement 3. Abstract P5-13-03).
14. Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, et al. A model of acquired autoresistance to apotent ErbB2 tyrosine kinaseinhibitor and atherapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A 2006;103:7795-800.
15. Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, et al. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 2011;29:166-73.
16. Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, Digiovanna MP, et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 2005;23:2460-8.
17. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
18. Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, et al. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res 2006;66:8266-73.
19. Rexer BN, Arteaga CL. Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications. Cancer Res 2013; 73:3817-20.
20. Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, et al. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol 2013;31:1726-31.
21. Lopez-Tarruella S, Schiff R. The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm. Clin Cancer Res 2007;13:6921-5.
22. Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, et al. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res 2010;12:R40.
23. Guo S, Sonenshein GE. Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol 2004;24:8681-90.
24. Bayliss J, Hilger A, Vishnu P, Diehl K, El-Ashry D. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clin Cancer Res 2007;13:7029-36.
25. Brinkman JA, El-Ashry D. ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers. J Mammary Gland Biol Neoplasia 2009;14:67-78.
26. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D. Activation of mitogen-activated protein kinase in estrogen receptor alphapositive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 2006;66:3903-11.
27. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol 2001;15:1344-59.
28. Plotkin A, Volmar CH, Wahlestedt C, Ayad N, El-Ashry D. Transcriptional repression of ER through hMAPK dependent histone deacetylation by class I HDACs. Breast Cancer Res Treat 2014;147:249-63.
29. Holloway JN, Murthy S, El-Ashry D. A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-alpha down-regulation in breast cancer cells: the role of nuclear factor-kappaB. Mol Endocrinol 2004;18:1396-410.
30. Gionet N, Jansson D, Mader S, Pratt MA. NF-kappaB and estrogen receptor alpha interactions: Differential function in estrogen receptor-negative and -positive hormone-independent breast cancer cells. J Cell Biochem 2009; 107:448-59.
31. Rimawi MF, Wang T, Rexer B, Forero A, Wolff AC, Nanda R, et al. TBCRC023: a randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endcorine therapy and without chemotherapy, for 12 vs. 24 weeks in patients with HER2 overexpressing breast cancer. Proc SABCS 2014. Abstract S6-01.
32. Lang JY, Hsu JL, Meric-Bernstam F, Chang CJ, Wang Q, Bao Y, et al. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell 2011;20:341-56.
33. Witters LM, Witkoski A, Planas-Silva MD, Berger M, Viallet J, Lipton A. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor. Oncol Rep 2007;17:465-9.
34. Crawford A, Nahta R. Targeting Bcl-2 in herceptin-resistant breast cancer cell lines. Curr Pharmacogenomics Person Med 2011;9:184-90.
35. Zoeller JJ, Gilmer TM, Selfors LM, Lu Y, Apple SK, Press MF, et al. Basement membrane localized tumor cells are protected from HER2-targeted therapy in vivo. Cancer research 2012;72:Supplement 3
36. Zoeller JJ, Gilmer TM, Selfors LM, Lu Y, Mills GB, Brugge JS. Abstract 4834: Basement membrane localized tumor cells are protected from HER2-targeted therapy in vivo. Cancer Res 2012;72:Supplement 1. Proceedings AACR Annual Meeting.
37. https://clinicaltrials.gov/ct2/results?term=NRG+B-52+&Search=Search.